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Protein-based therapeutics for rheumatoid arthritis have 
limitations despite improved clinical outcomes. In 
addition to expense and the need for parenteral adminis-
tration, a signiﬁ  cant percentage of patients do not have 
robust responses. Intracellular signaling molecules, such 
as members of the Rho family [1], represent an attractive 
alternative because the compounds are often orally 
bioavailable and can block numerous proinﬂ  ammatory 
mediators simultaneously.
Targeting signal transduction, however, has been an 
exercise in frustration until recently. Th  e p38 mitogen-
activated protein kinase saga is emblematic of these 
problems [2]. Despite abundant preclinical data 
supporting the utility of p38 inhibitors, beneﬁ  t has been 
marginal at best [3]. It is important to recognize that 
success in biologics also did not come with the ﬁ  rst 
attempt. Numerous failures preceded the advent of TNF 
blockers, including anti-CD4, anti-CD5 and anti-CD52 
antibodies, IL-2–diphtheria toxin fusion protein, IFNγ, 
IL-2, and several others. Clinical eﬃ   cacy for JAK and Syk 
inhibitors demonstrated in recent years crossed the 
Rubicon for signaling-directed therapeutics [4,5]. Th  e 
question now is not whether some of these agents can be 
eﬀ  ective; rather, it is whether the toxicity and side eﬀ  ects 
will be acceptable in a world where biologics have an 
advantageous therapeutic index.
A distinguishing feature of the encouraging inter-
ventions (Syk, JAK, and perhaps c-Kit) compared with 
p38 inhibitors is that the former targets are proximal in 
the signaling cascade. Going upstream can be risky, since 
each enzyme casts a broader penumbra of eﬀ  ects than a 
downstream target. Th   is increases the potential for both 
beneﬁ  t and toxicity. Risk, however, can be managed; lack 
of eﬃ   cacy cannot.
Th  is lesson is being exploited by going far upstream 
using therapeutics that inhibit the Rac proteins. Th  ese 
signaling enzymes, unlike the classical protein kinases 
that phosphorylate various transcription factors, are 
GTPases in the Rho family [6]. Th   ey regulate a vast array 
of functions, including cell movement, proliferation, 
adhesion, and phagocytosis. Many of these functions 
result from the subsequent activation of downstream 
protein kinases, such as the mitogen-activated protein 
kinase family. Blocking Rac proteins, such as Rac1, could 
potentially suppress many mechanisms implicated in 
rheumatoid arthritis.
Tak and colleagues approached this problem with a 
peptide inhibitor in order to explore in vitro and in vivo
eﬀ   ects of Rac1 inhibition [1]. Th  e peptide decreased 
production of key cytokines like IFNγ, TNF, and IL-17 by 
cultured T cells. Th   ey also examined the peptide’s eﬀ  ect 
in collagen-induced arthritis, a standard mouse model of 
rheumatoid arthritis [7].
Th   e use of peptide therapeutics in vivo is fraught with 
problems, such as a short half-life (often only minutes) 
and limited access to the intracellular space where the 
target actually resides. Despite this limitation, a modest 
decrease in paw swelling was observed along with a lower 
anti-type II collagen antibody titer. Interestingly, no 
signiﬁ  cant eﬀ  ect was observed on the clinical arthritis 
scores or histologic evidence of joint inﬂ  ammation and 
damage. If therapy was delayed until after disease was 
established, a nonsigniﬁ  cant trend toward decreased paw 
swelling was noted.
Several aspects of the study warrant comment. Th  e  lack 
of eﬀ  ect on clinical scores is interesting, as this usually 
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© 2010 BioMed Central Ltdtracks with paw swelling. Th  ese two endpoints, however, 
evaluate somewhat distinct phenomena. Th  e  former 
measures edema or tissue hyperplasia in a single joint 
(usually the ankle), while the latter determines the sum of 
the total number of active joints. It is possible to have 
relatively mild arthritis (and minimal swelling) with a high 
clinical score. Conversely, severe disease in the ankles but 
nowhere else could also lead to disparate outcomes. Th  e 
two indices of disease can thus provide complementary 
information. In this case, the lack of eﬀ   ect on joint 
destruction and synovial histology suggests that the Rac1 
inhibitory peptide might be acting through vascular 
leakage and tissue edema rather than immune cell 
inﬁ  ltration into the joint.
A second important point is that animal models are an 
imperfect representation of rheumatoid arthritis. Th  e 
kinetics of the synovial signaling pathway in mice is 
compressed compared with human disease, and the 
speciﬁ  c kinases engaged can vary from model to model 
[8]. Animal data must therefore be interpreted with some 
caution. Nevertheless, results for the Rac1 inhibitory 
peptide oﬀ  er a signal of eﬃ   cacy even though they probably 
underestimate the potential beneﬁ  t. A therapeutic agent 
with a longer blood half-life that is also optimized for cell 
penetration could give substantially better results. Th  e 
safety of blocking Rac1 cannot be accurately gauged with 
the peptide for the same reasons.
Overall, the future looks brighter for blocking signal 
molecules than it did a few years ago. With the plethora 
of potential targets, such as Rac, and armed with 
information on the biology of upstream rather than 
downstream molecules, there is renewed optimism for 
developing new therapeutics for rheumatoid arthritis.
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